February 21, 2017 / 12:30 PM / 5 months ago

BRIEF-Sarepta Therapeutics agrees to sale of priority review voucher for $125 mln

1 Min Read

Feb 21 (Reuters) - Sarepta Therapeutics Inc:

* Sarepta Therapeutics agrees to sale of priority review voucher for $125m

* Sale of PRV provides a significant infusion of non-dilutive capital

* Sarepta Therapeutics Inc - entered into an agreement to sell its rare pediatric disease priority review voucher

* Sarepta Therapeutics - received prv when exondys 51 was approved by U.S. FDA for treatment of patients with duchenne muscular dystrophy amenable to exon 51 skipping

* Sarepta Therapeutics Inc - as part of agreement, sarepta will receive an upfront payment of $125m upon closing of transaction Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below